-
Je něco špatně v tomto záznamu ?
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
P. Rodriguez-Otero, S. Usmani, AD. Cohen, NWCJ. van de Donk, X. Leleu, J. Gállego Pérez-Larraya, S. Manier, AK. Nooka, MV. Mateos, H. Einsele, M. Minnema, M. Cavo, BA. Derman, N. Puig, F. Gay, PJ. Ho, WJ. Chng, E. Kastritis, G. Gahrton, K....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem, směrnice pro lékařskou praxi
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- imunoterapie metody normy MeSH
- konsensus * MeSH
- lidé MeSH
- mnohočetný myelom * imunologie terapie farmakoterapie MeSH
- protilátky bispecifické * terapeutické užití MeSH
- protinádorové látky imunologicky aktivní terapeutické užití škodlivé účinky MeSH
- T-lymfocyty * imunologie účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have recently received regulatory approvals and shown unprecedented efficacy. However, these immunotherapies have unique mechanisms of action and toxicities that are different to previous treatments for myeloma, so experiences from clinical trials and early access programmes are essential for providing specific recommendations for management of patients, especially as these agents become available across many parts of the world. Here, we provide expert consensus clinical practice guidelines for the use of bispecific antibodies for the treatment of myeloma. The International Myeloma Working Group is also involved in the collection of prospective real-time data of patients treated with such immunotherapies, with the aim of learning continuously and adapting clinical practices to optimise the management of patients receiving immunotherapies.
Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam Netherlands
Amyloidosis Research and Treatment Center Fondazione IRCCS Policlinico San Matteo Pavia Italy
Cancer Center Clinica Universidad de Navarra CCUN Cima IDISNA CIBERONC Spain
Centre Hospitalier Universitaire Lille Universite de Lille Lille France
Centre Hospitalier Universitaire Poitiers Poitiers France
Department of Hemato oncology University Hospital Ostrava Ostrava Czech Republic
Department of Hematology Oncology National University Cancer Institute Singapore
Department of Hematology University Medical Center Utrecht Netherlands
Department of Medical Oncology Massachusetts General Hospital Boston MA USA
Department of Medicine 5 Multiple Myeloma Section University Hospital Heidelberg Heidelberg Germany
Department of Medicine Division of Hematology and Oncology University of Wisconsin Madison WI USA
Department of Medicine Karolinska Institutet Huddinge Stockholm Sweden
Dipartimento di Scieze Mediche e Chirurgiche Universitá di Bologna Bologna Italy
International Myeloma Foundation Studio City CA USA
IRCCS Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Bologna Italy
KG Jebsen Center for B Cell Malignancies University of Oslo Oslo Norway
MD Anderson Cancer Center University of Texas Houston TX USA
Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York NY USA
Oslo Myeloma Center Department of Hematology Oslo University Hospital Oslo Norway
Royal Prince Alfred Hospital and University of Sydney Sydney NSW Australia
Section of Hematology Oncology University of Chicago Chicago IL USA
Stanford University School of Medicine Stanford CA USA
Translational Genomics Research Institute City of Hope Cancer Center Phoenix AZ USA
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA USA
Universitätsklinikum Hamburg Eppendorf Medizinische Klinik und Poliklinik Hamburg Germany
Universitätsklinikum Würzburg Department of Internal Medicine 2 Würzburg Germany
University College London Hospitals London UK
University Hospital of Salamanca IBSAL Cancer Research Center IBMCC CIBERONC Salamanca Spain
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014057
- 003
- CZ-PrNML
- 005
- 20240905134041.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(24)00043-3 $2 doi
- 035 __
- $a (PubMed)38697166
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rodriguez-Otero, Paula $u Cancer Center Clinica Universidad de Navarra, CCUN, Cima, IDISNA, CIBERONC, Spain. Electronic address: paurodriguez@unav.es
- 245 10
- $a International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma / $c P. Rodriguez-Otero, S. Usmani, AD. Cohen, NWCJ. van de Donk, X. Leleu, J. Gállego Pérez-Larraya, S. Manier, AK. Nooka, MV. Mateos, H. Einsele, M. Minnema, M. Cavo, BA. Derman, N. Puig, F. Gay, PJ. Ho, WJ. Chng, E. Kastritis, G. Gahrton, K. Weisel, C. Nagarajan, F. Schjesvold, J. Mikhael, L. Costa, NS. Raje, E. Zamagni, R. Hájek, N. Weinhold, K. Yong, JC. Ye, S. Sidhana, G. Merlini, T. Martin, Y. Lin, A. Chari, R. Popat, JL. Kaufman, International Myeloma Working Group
- 520 9_
- $a Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have recently received regulatory approvals and shown unprecedented efficacy. However, these immunotherapies have unique mechanisms of action and toxicities that are different to previous treatments for myeloma, so experiences from clinical trials and early access programmes are essential for providing specific recommendations for management of patients, especially as these agents become available across many parts of the world. Here, we provide expert consensus clinical practice guidelines for the use of bispecific antibodies for the treatment of myeloma. The International Myeloma Working Group is also involved in the collection of prospective real-time data of patients treated with such immunotherapies, with the aim of learning continuously and adapting clinical practices to optimise the management of patients receiving immunotherapies.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a protilátky bispecifické $x terapeutické užití $7 D018033
- 650 12
- $a mnohočetný myelom $x imunologie $x terapie $x farmakoterapie $7 D009101
- 650 12
- $a konsensus $7 D032921
- 650 12
- $a T-lymfocyty $x imunologie $x účinky léků $7 D013601
- 650 _2
- $a imunoterapie $x metody $x normy $7 D007167
- 650 _2
- $a protinádorové látky imunologicky aktivní $x terapeutické užití $x škodlivé účinky $7 D000074322
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Usmani, Saad $u Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
- 700 1_
- $a Cohen, Adam D $u University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA
- 700 1_
- $a van de Donk, Niels W C J $u Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a Leleu, Xavier $u Centre Hospitalier Universitaire Poitiers, Poitiers, France
- 700 1_
- $a Gállego Pérez-Larraya, Jaime $u Department of Neurology, Clínica Universidad de Navarra, Cancer Center Clinica Universidad de Navarra, CCUN, Pamplona, Spain
- 700 1_
- $a Manier, Salomon $u Centre Hospitalier Universitaire Lille, Universite de Lille, Lille, France
- 700 1_
- $a Nooka, Ajay K $u Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA, USA
- 700 1_
- $a Mateos, Maria Victoria $u University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
- 700 1_
- $a Einsele, Hermann $u Universitätsklinikum Würzburg, Department of Internal Medicine II, Würzburg, Germany
- 700 1_
- $a Minnema, Monique $u Department of Hematology, University Medical Center, Utrecht, Netherlands
- 700 1_
- $a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Scieze Mediche e Chirurgiche, Universitá di Bologna, Bologna, Italy
- 700 1_
- $a Derman, Benjamin A $u Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
- 700 1_
- $a Puig, Noemi $u University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
- 700 1_
- $a Gay, Francesca $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Ho, P Joy $u Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Chng, Wee-Joo $u Department of Hematology-Oncology, National University Cancer Institute, Singapore
- 700 1_
- $a Kastritis, Efstathios $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Gahrton, Gösta $u Department of Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
- 700 1_
- $a Weisel, Katja $u Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik und Poliklinik, Hamburg, Germany
- 700 1_
- $a Nagarajan, Chandramouli $u Department of Haematology, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Singapore
- 700 1_
- $a Schjesvold, Fredik $u Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
- 700 1_
- $a Mikhael, Joseph $u Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA; International Myeloma Foundation, Studio City, CA, USA
- 700 1_
- $a Costa, Luciano $u Department of Medicine, Division of Hematology and Oncology, University of Wisconsin, Madison, WI, USA
- 700 1_
- $a Raje, Noopur S $u Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA
- 700 1_
- $a Zamagni, Elena $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Scieze Mediche e Chirurgiche, Universitá di Bologna, Bologna, Italy
- 700 1_
- $a Hájek, Roman $u Department of Hemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Weinhold, Niels $u Department of Medicine V, Multiple Myeloma Section, University Hospital Heidelberg, Heidelberg, Germany
- 700 1_
- $a Yong, Kwee $u University College London Hospitals, London, UK
- 700 1_
- $a Ye, Jing Christine $u MD Anderson Cancer Center, University of Texas, Houston, TX, USA
- 700 1_
- $a Sidhana, Surbhi $u Stanford University School of Medicine, Stanford, CA, USA
- 700 1_
- $a Merlini, Giampaolo $u Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 700 1_
- $a Martin, Tom $u UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
- 700 1_
- $a Lin, Yi $u Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Chari, Ajai $u UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
- 700 1_
- $a Popat, Rakesh $u NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK
- 700 1_
- $a Kaufman, Jonathan L $u Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA, USA
- 710 2_
- $a International Myeloma Working Group
- 773 0_
- $w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 25, č. 5 (2024), s. e205-e216
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38697166 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134035 $b ABA008
- 999 __
- $a ok $b bmc $g 2143688 $s 1225923
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 25 $c 5 $d e205-e216 $e - $i 1474-5488 $m Lancet oncology $n Lancet Oncol $x MED00011558
- LZP __
- $a Pubmed-20240725
